Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.4 million.

  • Tonix Pharmaceuticals Holding's Cost of Revenue fell 1209.0% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 2440.5%. This contributed to the annual value of $7.8 million for FY2024, which is 6378.4% up from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Cost of Revenue stood at $1.4 million for Q3 2025, which was down 1209.0% from $3.3 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Cost of Revenue high stood at $3.4 million for Q2 2024, and its period low was $943000.0 during Q1 2025.
  • Its 3-year average for Cost of Revenue is $2.0 million, with a median of $1.7 million in 2024.
  • Its Cost of Revenue has fluctuated over the past 5 years, first plummeted by 5002.11% in 2024, then crashed by 282.15% in 2025.
  • Tonix Pharmaceuticals Holding's Cost of Revenue (Quarter) stood at $2.4 million in 2023, then tumbled by 50.02% to $1.2 million in 2024, then grew by 15.55% to $1.4 million in 2025.
  • Its Cost of Revenue was $1.4 million in Q3 2025, compared to $3.3 million in Q2 2025 and $943000.0 in Q1 2025.